Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa
Phase Ib Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Volunteers in South Africa
Sponsor: Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site)
Listed as NCT01113281, this PHASE1 trial focuses on Tuberculosis and remains completed. Sponsored by Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site), it has been updated 6 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site)
- HJ-CTC George, RSA (Statistics & Report)
- Serum Life Science Europe GmbH
- Triclinium Johannesburg, RSA (Monitoring and Overall Management of the study)
- University of Stellenbosch
For direct contact, visit the study record on ClinicalTrials.gov .